# Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

> **NCT07725406** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Weill Medical College of Cornell University** · enrollment: 32 (estimated)

## Conditions studied

- Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Relapsed or Refractory Multiple Myeloma (MM)

## Interventions

- **DRUG:** Lymphodepleting chemotherapy: Cyclophosphamide
- **DRUG:** Lymphodepleting chemotherapy: Bendamustine
- **DRUG:** Lymphodepleting chemotherapy: Fludarabine
- **OTHER:** Lisocabtagene Maraleucel
- **OTHER:** Axicabtagene Ciloleucel
- **OTHER:** Ciltacabtagene Autoleucel
- **RADIATION:** Low-Dose Total Body Irradiation

## Key facts

- **NCT ID:** NCT07725406
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2028-08-01
- **Final completion:** 2033-08-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07725406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07725406, "Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07725406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*